references
FINANCIAL REPORT
c) Funding per project (restricted and unrestricted)
Operational Income (Grand TOTAL = 43,283,345) (Expressed in EUR)
UK Government DFID (1) (Unrestricted) Dutch Government DGIS (2) (Restricted) German Government KfW-BMBF (Restricted) Switzerland SDC (Unrestricted) French Government AFD (3) (Restricted) Norwegian Government (Restricted) Switzerland Canton of Geneva (Restricted)
EU FP7 (Restricted)
UNITAID (Restricted)
FACT (ASAQ & ASMQ fixed-dose) for Malaria Implementation & Development Nifurtimox + Eflornithine co-administration (NECT) for stage 2 for HAT New VL treatments (Asia, SSG & Paromo, Latin America; co infection HIV/VL) Fexinidazole for HAT Chagas Access Nitroimidazole VL-2098 (& back-up VL0690) for VL Macrofilaricide for Filaria (Flubendazole, Emodepside, TylAMac, Oxfendazole) Translation Combination Fexinidazole/ Miltefosine for VL Fexinidazole for Chagas Oxaborole SCYX-7158 for HAT Biomarkers for Chagas New Benz Regimen for Chagas Anfoleish for CL & CL Combination CpG-D35 (CL) + PKDL Paediatric HIV: PI sprinkles CHAPAS-2 & super boosting T. b./ HIV Lead Optimization Consortia (for VL, Chagas, and HAT), including Fenarimol series and Nitroimidazole & Oxaborole back-ups Discovery & Exploratory Kinetoplastids Filariasis Screening
Exploratory
123,368
12,871 16,295
329,771
27,826
15,909
81,501
357,207
1,329,949 103,495 270,684 4,113
191,831 227,431 176
212,922
306,516
75,186
116,667 294,792 3,586 194,871 69,972 412,486 60,229
65,481
158,450 133,963 252,921 2,138
59,334 150,523
30,532
706,010
199,851
44,171 2,758
27,000 41,172 4,631 240,997 1,881,666
2,477,820
147,653
391,487
198,818
Research
457,120 3,843 56,830 1,345,294 439,273 1,270,520 1,036,269 671,190 963,812
29,102
324,836 27,986
51,609
HCV, Mycetoma, Anti-infective R&D Coordination, Supervision costs HAT, LEAP, Filaria & Chagas Platforms Other Strengthening Capacity activities Advocacy Fundraising General Management Net surplus allocated to unrestricted funds Net surplus allocated to restricted funds TOTAL Income + other income
108,295 71,535
139,914 74,022
457,956 35,734 210,529 109,812 114 33 29,857 64,742 16,924 6,372 53,887 151,321 90,401
71,383 9,578 58,086
34,376 7,057 81,832 95,310 81,974
366,667 11,465 134,130
27,055 23,807 73,777 4,783 32,696 9,319 12,282
11,734,008
800,000 1,910,606 1,855,605 1,040,335 1,365,198 2,077,688
553,423
154,874
(1) UK Government, DFID: 1) an unrestricted grant of GBP 5.5 M (EUR 5,540,990), and an exceptional unrestricted grant of GBP 3 M (EUR 4,193,018) covering the period from Aug to Dec 2015 only. (2) The Netherlands Government, DGIS EUR 0.8 M with a new grant starting in Oct 2015. (3) French Government, AFD 1) A portfolio grant for malaria, HAT, and paediatric HIV EUR 912,462 and 2) a restricted grant to VL projects EUR 127,873. Requirement to open a specific bank account which bears its own financial result (4) GHIT 2015: a restricted grant of JPY 37,688,293 (EUR 282,129) for Chagas disease, a restricted grant of JPY 206,772,882 (EUR 1,549,753) for an early discovery project, and a restricted grant of JPY 28,409,954 (EUR 211,272) for NTD Booster project. (5) B&M Gates Foundation, includes four restricted grants and one portfolio grant: 1) EUR 729,455 for new VL treatments in Asia project; 2) EUR 147,771 for flubendazole macrofilaricide for the filarial programme terminated in Mar 2015; 3) EUR 97,206 for the Filarial screening programme terminating Mar 2015, 4) EUR 707,359 for an innovative fund terminating Dec 2015, and 5) EUR 12,240,783 as Portfolio grant for HAT, filarial programme, and discovery for leishmaniasis projects. Interests resulting from deferred incomes are
80 › DNDi Annual Report 2015